| Identification | Back Directory | [Name]
N1-(tert-butyl)-2-(2,4-dihydroxybenzylidene)hydrazine-1-carbothioamide | [CAS]
218795-74-5 | [Synonyms]
IMM-01
Intramimic-01
IMM-01
(IMM 01)
IMM-01 >=98% (HPLC)
IMM-01, 10 mM in DMSO
3-tert-butyl-1-[(E)-[(2,4-dihydroxyphenyl)methylidene]amino]thiourea
N1-(tert-butyl)-2-(2,4-dihydroxybenzylidene)hydrazine-1-carbothioamide
2-[(2,4-Dihydroxyphenyl)methylene]-N-(1,1-dimethylethyl)-hydrazinecarbothioamide
Hydrazinecarbothioamide, 2-[(2,4-dihydroxyphenyl)methylene]-N-(1,1-dimethylethyl)- | [Molecular Formula]
C12H17N3O2S | [MDL Number]
MFCD00096693 | [MOL File]
218795-74-5.mol | [Molecular Weight]
267.35 |
| Chemical Properties | Back Directory | [Boiling point ]
425.3±38.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble10mg/mL, clear | [form ]
powder | [pka]
7.77±0.40(Predicted) | [color ]
white to light brown |
| Hazard Information | Back Directory | [Uses]
IMM-01 has been used as a formin activator to study its effects on motor neurons (MNs). | [Biological Activity]
Primary Target
mDia''Reversible: yes | [in vivo]
IMM-01 (5-25 mg/kg; i.v.; 2 times a week; for 3 weeks) is able to slow tumor growth in a mouse xenograft model of colon cancer[1]. | Animal Model: | Athymic nude female mice (6 to 8 weeks) implanted with SW480 cells[1] | | Dosage: | 5 mg/kg, 25 mg/kg | | Administration: | i.v.; 2 times a week; for 3 weeks | | Result: | Slowed tumor growth in a dose-dependent manner when administered intravenously via the tail vein.
|
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
http://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|